- Current status
- AHSCT is a standard of care of RRMS
- Wykłady na kursie specjalizacyjnym – transplantologia
- AHSCT is better choice than DMDs in MS as a treatment of cases progressing after first line treatment – multicenter randomised trial.
- CPX-351 (Vyxeos) – new drug that improves treatment in older patients with secondary AML
Monthly Archives: September 2017
I have prepared (in polish) new presentation on news and progress in clinical use of cord blood. Time will tell what it will be used to – I am sure that there are some properties that are hard to replicate … Continue reading
This is the moment which is important – the CART cells are finally acknowledged by FDA – which means that they can be used as treatment. The price – still too high for them to be used widely – hopefully … Continue reading